Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.34 |
| ▸ | USP2 | O75604 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24940878 | 0.90 | CYP2D6 (0.37) | CYP2D6CYP3A4USP2TSHRCYP1A2 | |
| SCHEMBL17624449 | 0.89 | CYP3A4 (0.39) | CYP2D6CYP3A4USP2TSHRCYP1A2 | |
| SCHEMBL25044367 | 0.89 | HSD17B10 (0.35) | CYP2D6CYP3A4USP2TSHRCYP1A2 | |
| SCHEMBL19504447 | 0.84 | KDM1A (0.31) | HSD17B10 | |
| SCHEMBL25044369 | 0.82 | HSD17B10 (0.39) | CYP2D6CYP3A4USP2TSHRCYP1A2 | |
| SCHEMBL25001373 | 0.80 | CYP2D6 (0.41) | CYP2D6CYP3A4TSHRCYP1A2ALDH1A1 | |
| SCHEMBL18517453 | 0.77 | TSHR (0.43) | CYP2D6CYP3A4USP2TSHRCYP1A2 | |
| SCHEMBL24747086 | 0.76 | TSHR (0.46) | CYP2D6CYP3A4USP2TSHRCYP1A2 | |
| SCHEMBL18390931 | 0.75 | TSHR (0.53) | USP2TSHROPRM1 | |
| SCHEMBL27283008 | 0.75 | CYP2D6 (0.32) | CYP2D6CYP3A4USP2CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016044604-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | CYP2D6 3645/4885CYP3A4 2855/4885USP2 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.